Radical Numerics launches Omnii-1 genome model and says its AI-designed phages were given to a patient with a drug-resistant infection; outcome not disclosed

Why it matters

【Key points】

Radical Numerics released Omnii-1, a genome language model, on Oct 20, and says phages it designed were given to a patient with an antibiotic-resistant infection under compassionate use, the first clinical use of AI-generated phages.

1. Model: pretrained on trillions of tokens across 28 biological modalities, including DNA, RNA, proteins, chromatin accessibility, DNA methylation and gene expression, then adapted through mid- and post-training. It is a research preview with access by request.

2. Phage design (company tests): at 11-15 amino-acid changes, 69.9% of designs were recovered as phages versus 4.8% of random controls; 2,161 of 6,694 variants with measurable activity beat wild type. For held-out E. coli strains, its top two picks included an active phage 92.1% of the time.

3. Clinical use: a cocktail with Omnii-1 variants cleared the patient's resistant isolate in the lab and was then given under an authorized, physician-led compassionate-use pathway. The company did not disclose the clinical course or outcome, citing privacy.

4. It also announced eight applications, including genome regulation, rare-disease genetics, cancer-detection biomarkers, antibodies and biodefense.

【Verifiable】

Phage study: https://www.radicalnumerics.ai/blog/omnii-phage

Omnii-1 overview: https://www.radicalnumerics.ai/blog/omnii-1

CEO Eric Nguyen post: https://x.com/exnx/status/2112580926651904379

【Our read】

1. AI-designed biological sequences reaching a patient is a concrete milestone for AI drug design.

2. It is one patient, with no disclosed outcome and no peer review; the company says a single case cannot show safety or efficacy. Claims online of "FDA authorization" or a cure are not in its posts.

3. All benchmark numbers are the company's own; Omnii-1 has no downloadable weights and is offered only as a by-request research preview and a restricted biodefense API.